4/A: Arcutis Biotherapeutics Director Corrects Ownership Filing

Director Patrick J. Heron filed an amendment to correct a scrivener's error regarding his indirect beneficial ownership of Arcutis Biotherapeutics shares.

Summary

• This Form 4/A serves as an amendment to a previously filed Form 4 dated June 9, 2026.
• The filing corrects a reporting error concerning the number of shares held indirectly by Director Patrick J. Heron through Frazier Life Sciences X, L.P.
• The original filing understated the indirect beneficial ownership by 2,646 shares.
• The corrected total of shares held indirectly is now reported as 27,448.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as it is a routine administrative correction with no impact on the company's financial or operational status.

Positives

• The filing demonstrates transparency and regulatory compliance by proactively correcting a clerical error.

Negatives

• The initial filing contained a scrivener's error, indicating a minor lapse in administrative reporting accuracy.

Risks

• None identified; this is a purely administrative correction.

Future Outlook

Not applicable; this is a retrospective administrative correction.

Industry Context

StockSavvy.ai notes that administrative amendments to Section 16 filings are common in the biotech sector, where complex ownership structures involving venture capital firms often lead to minor reporting discrepancies.

Comparison to Industry Standards

• The correction follows standard SEC protocols for rectifying clerical errors in beneficial ownership reporting.

Related Party Transactions

• The reporting person is a managing member of the general partner of Frazier Life Sciences X, L.P., which holds the shares.

Stakeholder Impact

• No material impact on shareholders or company operations.

Key Dates

Keywords

Arcutis Biotherapeutics, ARQT, Form 4/A, Insider Ownership, Frazier Life Sciences, SEC Filing